Key Details
Price
$1.05Annual ROE
-20.77%Beta
1.40Events Calendar
Next earnings date:
Mar 07, 2025Recent quarterly earnings:
Nov 12, 2024Recent annual earnings:
Mar 08, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
Nov 06, 2020Analyst ratings
Recent major analysts updates
23 Oct '24 Canaccord Genuity
Buy15 Aug '24 HC Wainwright & Co.
Buy14 Aug '24 Canaccord Genuity
Buy13 May '24 HC Wainwright & Co.
Buy13 May '24 Canaccord Genuity
BuyScreeners with IRD included
No data
Market Data
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Dividend
Opus Genetics doesn't have historical dividend data
Profitability
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Efficiency
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Valuation
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Liquidity
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Cash Flow
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Institutional Ownership
Opus Genetics, Inc. (IRD) Reports Q3 Loss, Tops Revenue Estimates
IRD
zacks.com12 November 2024
Opus Genetics, Inc. (IRD) came out with a quarterly loss of $0.29 per share versus the Zacks Consensus Estimate of a loss of $0.30. This compares to earnings of $0.25 per share a year ago.
FAQ
- What is the primary business of Opus Genetics?
- What is the ticker symbol for Opus Genetics?
- Does Opus Genetics pay dividends?
- What sector is Opus Genetics in?
- What industry is Opus Genetics in?
- What country is Opus Genetics based in?
- When did Opus Genetics go public?
- Is Opus Genetics in the S&P 500?
- Is Opus Genetics in the NASDAQ 100?
- Is Opus Genetics in the Dow Jones?
- When was Opus Genetics's last earnings report?
- When does Opus Genetics report earnings?
- Should I buy Opus Genetics stock now?
What is the primary business of Opus Genetics?
Opus Genetics, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. The company offers Phentolamine Ophthalmic Solution for reversal of mydriasis, as well as is in Phase III clinical trials for presbyopia and dim light or night vision disturbances. Its lead retinal product candidate is APX3330, a small-molecule inhibitor of reduction oxidation effector factor-1 protein that has completed Phase II clinical trial for the treatment of diabetic retinopathy. The company also develops APX2009 and APX2014 that are preclinical product candidates for retina indications. The company was formerly known as Ocuphire Pharma, Inc. Opus Genetics, Inc. was founded in 2018 and is headquartered in Farmington Hills, Michigan.
What is the ticker symbol for Opus Genetics?
The ticker symbol for Opus Genetics is NASDAQ:IRD
Does Opus Genetics pay dividends?
No, Opus Genetics does not pay dividends
What sector is Opus Genetics in?
Opus Genetics is in the Healthcare sector
What industry is Opus Genetics in?
Opus Genetics is in the Biotechnology industry
What country is Opus Genetics based in?
Opus Genetics is headquartered in United States
When did Opus Genetics go public?
Opus Genetics's initial public offering (IPO) was on 19 January 2015
Is Opus Genetics in the S&P 500?
No, Opus Genetics is not included in the S&P 500 index
Is Opus Genetics in the NASDAQ 100?
No, Opus Genetics is not included in the NASDAQ 100 index
Is Opus Genetics in the Dow Jones?
No, Opus Genetics is not included in the Dow Jones index
When was Opus Genetics's last earnings report?
Opus Genetics's most recent earnings report was on 12 November 2024
When does Opus Genetics report earnings?
The next expected earnings date for Opus Genetics is 7 March 2025
Should I buy Opus Genetics stock now?
As of today, analysts generally recommend a 'Strong buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions